The National Institutes of Health is teaming up with major drug companies in a new effort to identify diseaserelated molecules and biological processes that could lead to future medicines The publicprivate partnership is called   for the Accelerating Medicines Partnership and it will focus first on Alzheimers disease Type  diabetes and two autoimmune disorders rheumatoid arthritis and lupus This is a fiveyear  million venture NIH is splitting the cost with industry In addition to ten companies that include Pfizer Merck and Johnson  Johnson nonprofits like the American Diabetes Association and the Alzheimers Association have also joined Theyll work together to identify the most promising biological targets for new therapies All the scientific data produced by the venture will be shared publicly Even if we werent working with companies we would do this says   director of the NIH He officially unveiled the partnership at a press event in Washington DC and in a       on the venture late Monday Collins says after new targets are found companies can then develop drugs that take advantage of them The goal is to speed new therapies to market while avoiding the costly and disappointing failures that currently plague the drugdevelopment process The project will be managed by the   Its   that pharmaceutical companies have come together under its leadership to form research consortiums What sets this venture apart is its comprehensive approach in prioritizing diseases where the science is evolving and patients needs are pressing plus the breadth of this many companies and the NIH working together says   head of research and development at Pfizer I have considerable enthusiasm that this is unique says Dolsten Its complementary and we should aspire high here Hopefully the collaboration will help illuminate the fundamental basis of whats driving disease says Lisa Olson vice president of immunology research at AbbVie Bioresearch Center Inc one of the industry partners Asked if she had seen a partnership similar to this one before she said simply No